Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intralesional LAK Cells and Aldesleukin for Glioblastoma
NCT00331526Phase 2Completed
- Sponsor
- Hoag Memorial Hospital Presbyterian
- Start
- Feb 1999
- Primary completion
- Dec 2008
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lymphokine-activated killer cells in glioblastoma multiforme (GBM), sponsored by Hoag Memorial Hospital Presbyterian. Primary endpoints: Feasibility, side effects, and toxicity, Progression-Free Survival and 1 more. Started Feb 1999; status: completed.
02
Drugs
lymphokine-activated killer cells
03
Conditions
glioblastoma multiforme (GBM)
Beyond the preview
Go deeper on NCT00331526.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00331526.